A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Controlled, Multi-center Phase 2 Clinical study to Investigate
the Efficacy and Safety of Tucidinostat (Chidamide) Combined with Tislelizumab as First-line
Treatment for PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.